Ca. 150 people gathered on Zoom on October 14th to hear an update on the different clinical trials that’s going on in OI at the moment. Lot’s of questions and interaction. Two of the trials are still recruiting: – The Losartan trial (adults) – The Evenity trial (children with OI) Are you or your child…
An amazing number of 278 people from 55 countries (marked in blue on the map) signed up for the OIFE Clinical Trial Update which took place October 22nd, showing that OIFE’s outreach is growing year by year. In the end we were around 130 participants who received lots of information and updates from the following…
OIFE supports and encourages the advancement into research to find new treatments, improve diagnosis and aid a better understanding of OI. We strive to keep the OI community informed of what clinical trials are ongoing. As part of this we are hosting our 2nd clinical trial update webinar on October the 22nd, 2024. The goal…
On the 24th of October, OIFE hosted a webinar for the OI community about clinical trials and updates. 235 people from 52 countries signed up. Attendees were a mix of health professionals, scientists, OI clinicians, industry professionals, and individuals with OI and their family members. OIFE is excited to share this current OI study and…
We invite you to register for a 1,5 hour webinar called “Clinical Trial Update 2023”. GOAL & TARGET GROUP The goal of the webinar is to update the OI-community about ongoing clinical trials – both those who are recruiting and others. The target group is anyone interested in OI-related research – both professionals and people…
Interview with Dr. Winnie Liu, Oregon Health and Science University (OHSU), Portland, Oregon, USA Dr. Winnie Liu is an adult endocrinologist and takes care of patients at Oregon Health and Science University (OHSU) located in Portland, Oregon. Her clinical and research interests are metabolic bone disease with a focus on OI after joining the BBDC (Brittle…
TOPaZ is a randomised open-label clinical trial for people with osteogenesis imperfecta (OI). The study aims to investigate whether a two-year spell of treatment with a drug called teriparatide (TPTD) followed by treatment with another drug called Zoledronic acid (ZA) reduces the risk of broken bones occurring in people with OI. The TOPaZ trial receives…
Treatment of OI with Parathyroid hormone and Zoledronic acid Interview with Prof. Stuart H. Ralston, University of Edinburgh, Western General Hospital, UK Who are you & what is your relationship to OI? I am a physician and rheumatologist with a special interest in the treatment of bone diseases. I have been taking care of patients…
